D-Cycloserine augmentation of cognitive remediation in schizophrenia

Schizophrenia Research

Volumn 153, Issue 1-3, 2014, Pages 177-183

  Cain, Christopher K ^a,b   McCue, Margaret ^b   Bello, Iruma ^a   Creedon, Timothy ^c   Tang, Dei in ^b   Laska, Eugene ^b   Goff, Donald C ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cognitive remediation; D Cycloserine; MATRICS; Memory; SANS; Schizophrenia

Indexed keywords

CYCLOSERINE; PLACEBO; ANTIMETABOLITE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUDITORY DISCRIMINATION; COGNITION; COGNITIVE REMEDIATION; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRICS COGNITIVE BATTERY COMPOSITE SCORE; MENTAL TASK; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVE CELL PLASTICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; TREATMENT DURATION; AUDITORY STIMULATION; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PERCEPTIVE DISCRIMINATION; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SINGLE BLIND PROCEDURE;

ACOUSTIC STIMULATION; ADULT; ANTIMETABOLITES; COGNITION DISORDERS; COGNITIVE THERAPY; CYCLOSERINE; DISCRIMINATION (PSYCHOLOGY); FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SINGLE-BLIND METHOD;

EID: 84895782150     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.01.016     Document Type: Article

References (59)

1. Adcock R.A., Dale C., Fisher M., Aldebot S., Genevsky A., Simpson G.V., Nagarajan S., Vinogradov S. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr. Bull. 2009, 35(6):1132-1141.
2. Ahissar M., Nahum M., Nelken I., Hochstein S. Reverse hierarchies and sensory learning. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2009, 364(1515):285-299.
3. Bailey J.E., Papadopoulos A., Lingford-Hughes A., Nutt D.J. d-Cycloserine and performance under different states of anxiety in healthy volunteers. Psychopharmacology (Berl) 2007, 193(4):579-585.
4. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33(9):2175-2186.
5. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164(10):1593-1602.
6. Burgos-Robles A., Vidal-Gonzalez I., Santini E., Quirk G.J. Consolidation of fear extinction requires NMDA receptor-dependent bursting in the ventromedial prefrontal cortex. Neuron 2007, 53(6):871-880.
7. Cain C.K., Blouin A.M., Barad M. Adrenergic transmission facilitates extinction of conditional fear in mice. Learn. Mem. 2004, 11(2):179-187.
8. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J. Neural Transm. Gen. Sect. 1994, 95:105-111.
9. Dale C.L., Findlay A.M., Adcock R.A., Vertinski M., Fisher M., Genevsky A., Aldebot S., Subramaniam K., Luks T.L., Simpson G.V., Nagarajan S.S., Vinogradov S. Timing is everything: neural response dynamics during syllable processing and its relation to higher-order cognition in schizophrenia and healthy comparison subjects. Int. J. Psychophysiol. 2010, 75(2):183-193.
10. Daskalakis Z.J., Christensen B.K., Fitzgerald P.B., Chen R. Dysfunctional neural plasticity in patients with schizophrenia. Arch. Gen. Psychiatry 2008, 65(4):378-385.
11. Davis M. NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin. Neurosci. 2011, 13(4):463-474.
12. Davis M., Ressler K., Rothbaum B.O., Richardson R. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol. Psychiatry 2006, 60(4):369-375.
13. Dickinson D., Tenhula W., Morris S., Brown C., Peer J., Spencer K., Li L., Gold J.M., Bellack A.S. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia. Am. J. Psychiatry 2010, 167(2):170-180.
14. Dix S., Gilmour G., Potts S., Smith J.W., Tricklebank M. A within-subject cognitive battery in the rat: differential effects of NMDA receptor antagonists. Psychopharmacology (Berl) 2010, 212(2):227-242.
15. Dravid S.M., Burger P.B., Prakash A., Geballe M.T., Yadav R., Le P., Vellano K., Snyder J.P., Traynelis S.F. Structural determinants of d-cycloserine efficacy at the NR1/NR2C NMDA receptors. J. Neurosci. 2010, 30(7):2741-2754.
16. Dunn M.J., Killcross S. Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance. Behav. Brain Res. 2006, 175(2):271-277.
17. Fisher M., Holland C., Merzenich M.M., Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 2009, 166(7):805-811.
18. Flood J., Morley J., Lanthorn T. Effect on memory processing by d-cycloserine, an agonist of the NMDA/glycine receptor. Eur. J. Pharmacol. 1992, 221:249-254.
19. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry 1995, 152:1213-1215.
20. Goff D., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D., Hayden D., McCarley R., Coyle J. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry 1999, 56:21-27.
21. Goff D.C., Cather C., Gottlieb J.D., Evins A.E., Walsh J., Raeke L., Otto M.W., Schoenfeld D., Green M.F. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr. Res. 2008, 106(2-3):320-327.
22. Goff D.C., Hill M., Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol. Biochem. Behav. 2011, 99(2):245-253.
23. Gottlieb J.D., Cather C., Shanahan M., Creedon T., Macklin E.A., Goff D.C. d-Cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr. Res. 2011, 131:69-74.
24. Gupta S.C., Hillman B.G., Prakash A., Ugale R.R., Stairs D.J., Dravid S.M. Effect of d-cycloserine in conjunction with fear extinction training on extracellular signal-regulated kinase activation in the medial prefrontal cortex and amygdala in rat. Eur. J. Neurosci. 2013, 37(11):1811-1822.
25. Hillman B.G., Gupta S.C., Stairs D.J., Buonanno A., Dravid S.M. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol. Learn. Mem. 2011, 95(4):404-414.
26. Holt D.J., Lebron-Milad K., Milad M.R., Rauch S.L., Pitman R.K., Orr S.P., Cassidy B.S., Walsh J.P., Goff D.C. Extinction memory is impaired in schizophrenia. Biol. Psychiatry 2009, 65(6):455-463.
27. Holt D.J., Coombs G., Zeidan M.A., Goff D.C., Milad M.R. Failure of neural responses to safety cues in schizophrenia. Arch. Gen. Psychiatry 2012, 69(9):893-903.
28. Hooker C.I., Bruce L., Fisher M., Verosky S.C., Miyakawa A., Vinogradov S. Neural activity during emotion recognition after combined cognitive plus social cognitive training in schizophrenia. Schizophr. Res. 2012, 139(1-3):53-59.
29. Kalisch R., Holt B., Petrovic P., De Martino B., Kloppel S., Buchel C., Dolan R.J. The NMDA agonist d-cycloserine facilitates fear memory consolidation in humans. Cereb. Cortex 2009, 19(1):187-196.
30. Kandel E.R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001, 294(5544):1030-1038.
31. Keefe R.S., Vinogradov S., Medalia A., Buckley P.F., Caroff S.N., et al. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J. Clin. Psychiatry 2012, 73:1016-1022.
32. Langton J.M., Richardson R. d-Cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33(13):3096-3102.
33. Lee J.L., Milton A.L., Everitt B.J. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J. Neurosci. 2006, 26(39):10051-10056.
34. Lisman J.E., Pi H.J., Zhang Y., Otmakhova N.A. A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia. Biol. Psychiatry 2010, 68(1):17-24.
35. Manoach D.S., Thakkar K.N., Stroynowski E., Ely A., McKinley S.K., Wamsley E., Djonlagic I., Vangel M.G., Goff D.C., Stickgold R. Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. J. Psychiatr. Res. 2010, 44(2):112-120.
36. Matsuoka N., Aigner T.G. d-Cycloserine, a partial agonist at the glycine site coupled to N-methyl-d-aspartate receptors, improves visual recognition memory in rhesus monkeys. J. Pharmacol. Exp. Ther. 1996, 278:891-897.
37. Murthy N.V., Mahncke H., Wexler B.E., Maruff P., Inamdar A., Zucchetto M., Lund J., Shabbir S., Shergill S., Keshavan M., Kapur S., Laruelle M., Alexander R. Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study. Schizophr. Res. 2012, 139(1-3):87-91.
38. Nitsche M.A., Jaussi W., Liebetanz D., Lang N., Tergau F., Paulus W. Consolidation of human motor cortical neuroplasticity by d-cycloserine. Neuropsychopharmacology 2004, 29(8):1573-1578.
39. Norberg M.M., Krystal J.H., Tolin D.F. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry 2008, 63(12):1118-1126.
40. Ogden K.K., Khatri A., Traynelis S.F., Heldt S.A. Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice. Neuropsychopharmacology 2014, 39(3):625-637.
41. Otto M.W., Basden S.L., McHugh R.K., Kantak K.M., Deckersbach T., Cather C., Goff D.C., Hofmann S.G., Berry A.C., Smits J.A. Effects of d-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychother. Psychosom. 2009, 78(1):49-54.
42. Parnas A.S., Weber M., Richardson R. Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats. Neurobiol. Learn. Mem. 2005, 83(3):224-231.
43. Quartermain D., Mower J., Rafferty M.F., Herting R.L., Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur. J. Pharmacol. 1994, 257:7-12.
44. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., Hodges L., Davis M. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 2004, 61:1136-1144.
45. Schicknick H., Tischmeyer W. Consolidation of auditory cortex-dependent memory requires N-methyl-d-aspartate receptor activation. Neuropharmacology 2006, 50(6):671-676.
46. Smits J.A., Rosenfield D., Otto M.W., Marques L., Davis M.L., Meuret A.E., Simon N.M., Pollack M.H., Hofmann S.G. d-Cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J. Psychiatr. Res. 2013, 47:1455-1461.
47. Smits J.A., Rosenfield D., Otto M.W., Powers M.B., Hofmann S.G., Telch M.J., Pollack M.H., Tart C.D. d-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol. Psychiatry 2013, 73:1054-1058.
48. Sotres-Bayon F., Diaz-Mataix L., Bush D.E., LeDoux J.E. Dissociable roles for the ventromedial prefrontal cortex and amygdala in fear extinction: NR2B contribution. Cereb. Cortex 2009, 19(2):474-482.
49. Suryavanshi P.S., Ugale R.R., Yilmazer-Hanke D., Stairs D.J., Dravid S.M. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br. J. Pharmacol 2013, (Nov 14 [Epub ahead of print] PubMed PMID: 24236947). 10.1111/bph.12518.
50. Tan S., Kirk R.C., Abraham W.C., McNaughton N. Effects of the NMDA antagonists CPP and MK-801 on delayed conditional discrimination. Psychopharmacology (Berl) 1989, 98(4):556-560.
51. Thompson L.T., Disterhoft J.F. Age- and dose-dependent facilitation of associative eyeblink conditioning by d-cycloserine in rabbits. Behav. Neurosci. 1997, 111(6):1303-1312.
52. Walker D.L., Ressler K.J., Lu K.T., Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci. 2002, 22(6):2343-2351.
53. Wamsley E.J., Tucker M.A., Shinn A.K., Ono K.E., McKinley S.K., Ely A.V., Goff D.C., Stickgold R., Manoach D.S. Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation?. Biol. Psychiatry 2012, 71(2):154-161.
54. Watanabe Y., Saito H., Abe K. Effects of glycine and structurally related amino acids on generation of long-term potentiation in rat hippocampal slices. Eur. J. Pharmacol. 1992, 223(2-3):179-184.
55. Weickert C.S., Fung S.J., Catts V.S., Schofield P.R., Allen K.M., Moore L.T., Newell K.A., Pellen D., Huang X.F., Catts S.V., Weickert T.W. Molecular evidence of N-methyl-d-aspartate receptor hypofunction in schizophrenia. Mol. Psychiatry 2013, 18:1185-1192.
56. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobar P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168:472-485.
57. Yang Y.L., Lu K.T. Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. Neuroscience 2005, 134:247-260.
58. Yu H., Wang Y., Pattwell S., Jing D., Liu T., Zhang Y., Bath K.G., Lee F.S., Chen Z.Y. Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J. Neurosci. 2009, 29(13):4056-4064.
59. Yurgelun-Todd D.A., Coyle J.T., Gruber S.A., Renshaw P.F., Silveri M.M., Amico E., Cohen B., Goff D.C. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserine. Psychiatry Res. 2005, 138(1):23-31.